RxDoctor Payments Data

Gustavo Bendeck, PA

Physician Assistant · Slaton, TXNPI 1336252220

Payments from drug & device makers

$745in general payments, 2019–2025

Across 18 payments — averaging $41.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$180
  • Boehringer Ingelheim$111
  • Lilly USA, LLC$106
  • Axsome Therapeutics, Inc.$90
  • Smith+Nephew$69
  • Baxter Healthcare$44
  • plus $146 from 7 others

What the payments were for

  • Food & beverage$745100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$745 in reported general payments places this provider in the 60th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$1,899
Medicare patients
14
Services billed
43

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide70$98,381
FarxigaDapagliflozin Propanediol68$72,643
OzempicSemaglutide38$48,138
Tresiba Flextouch U-200Insulin Degludec51$46,864
EliquisApixaban35$25,155
JardianceEmpagliflozin19$23,749
VraylarCariprazine Hcl13$17,983
TrulicityDulaglutide11$16,943
SymbicortBudesonide/Formoterol Fumarate13$2,930
Albuterol Sulfate HfaAlbuterol Sulfate94$2,888
Gabapentin123$2,729
Celecoxib72$2,671
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$2,544
Metoprolol Succinate175$2,070
Nano 2nd Gen Pen NeedlePen Needle, Diabetic24$1,977

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$106$115,32481 claims
Novo NordiskOzempic$26$48,13838 claims
Boehringer IngelheimJardiance$111$23,74919 claims
AbbVieVraylar$25$17,98313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Slaton

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →